comparemela.com

Taiwan Health Ph News Today : Breaking News, Live Updates & Top Stories | Vimarsana

個股:生華科(6492)治新冠重症二期臨床,期中數據獲美DMC審查通過_富聯網

個股:生華科(6492)治新冠重症二期臨床,期中數據獲美DMC審查通過_富聯網
money-link.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from money-link.com.tw Daily Mail and Mail on Sunday newspapers.

《生醫股》生華科新藥納入CDE新冠專案 加速開發目標全球首款口服藥 - 財經

生華科(6492)開發中新藥Silmitasertib,日前已獲TFDA核准以恩慈專案治療新冠重症患者,為擴大應用,生華科今天公告新藥Silmitasertib已獲納入由財團法人醫藥品查驗中心(CDE)主導之「CDE can Help:COVID-19專案法規

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.